癌症患者如何跟踪他们的病人旅程?
Anna Grøndahl Larsen1, Ragnhild Halvorsrud1, Ingrid Konstanse Ledel Solem1
1SINTEF Digital, Norway.
Studies in health technology and informatics
|August 23, 2024
概括
癌症患者使用各种工具积极管理他们的治疗旅程. 虽然国家患者门户提供了一些好处,但它们并不完全满足患者信息需求.
科学领域:
- 在瘤学瘤学.
- 患者体验 患者体验
- 医疗信息学 医疗信息学
背景情况:
- 癌症治疗涉及长期,复杂的患者旅程,需要广泛的管理.
- 患者及其亲属在跟踪预约和治疗计划方面面临挑战.
研究的目的:
- 研究癌症患者及其亲属在管理患者旅程时采用的策略.
- 评估国家患者门户网站在支持癌症患者自我管理方面的实用性.
主要方法:
- 这是一项定性研究,涉及41名癌症患者及其近亲.
- 专注于了解患者主导的治疗和随访管理策略.
主要成果:
- 大多数癌症患者在管理他们的医疗保健旅程中发挥积极作用.
- 患者利用各种各样的工具来组织他们的治疗和信息.
- 国家患者门户网站被认为有助于信息获取和概述,但本身就不足.
结论:
- 癌症患者积极主动地管理他们的旅程,采用多种自我管理策略.
- 目前的数字健康工具,包括国家患者门户网站,需要加强,以充分解决患者信息和管理需求.
相关概念视频
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Methods of Documentation VI: Case Management Model
564
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
564
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


